BioSpace News Archive

Theralase Technologies Inc. announced today an update on its recently reported Phase II clinical study (“Study II”) interim clinical data.

[10-May-2023] DURHAM, N.C. , May 10, 2023 /PRNewswire/ -- Young children, ages 2 to 4 years, especially those with parental history of asthma, suffered the highest rates of asthma with recurrent exacerbations (ARE) over a nearly 30-year period studied in new research funded by the Environmental influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health.

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments.

Quest Diagnostics Incorporated, through the Quest Diagnostics Foundation, is proud to support the American Heart Association ‘s Hispanic Serving Institutions Scholars Program for the second year in a row.

Regulatory News: Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, provides a business update, including its financial position as of March 31, 2023.

Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023.

After practicing at leading surgical centers in New York and California, Dr. Brian Fiani, DO, joins Mendelson Kornblum Orthopedics and Spine Specialists in his home state of Michigan.

Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that the U.S. Food and Drug Administration’s Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee voted unanimously 17 to 0, with no abstentions, that the benefits of making Opill®, a progestin-only daily oral contraceptive, available for over-the-counter use outweighs the risks.

Vanda Pharmaceuticals Inc. responded to the ruling in its Hetlioz® Abbreviated New Drug Application appeal.